Somatostatin Tablet

Diabetic Ketoacidosis (DKA) is a severe metabolic disorder caused by absolute or relative insulin deficiency combined with excessive secretion of counter-regulatory hormones. It is one of the most common acute complications of diabetes, characterized clinically by hyperglycemia, hyperketonemia, and metabolic acidosis. Clinical manifestations include polyuria, polydipsia, deep and rapid breathing with a fruity odor on the breath. In severe cases, disturbance of consciousness, coma, and even life-threatening conditions may occur.

Current clinical treatments for DKA focus on fluid replacement, low-dose intravenous insulin infusion, correction of electrolyte and acid-base imbalance, and removal of triggers. However, in some refractory cases or patients with multiple complications, conventional therapy alone yields unsatisfactory results: slow blood glucose reduction, difficult-to-correct ketosis, and even recurrent episodes. Adjuvant drugs are therefore needed to enhance efficacy and prevent complications. As a synthetic oral peptide drug, somatostatin tablet plays an important role in the adjuvant treatment of DKA via its unique pharmacological effects, especially in suppressing glucagon secretion, relieving ketosis, and reducing complication risks.

Some DKA patients, after standardized conventional treatment (adequate fluid replacement, low-dose insulin infusion, correction of electrolyte disorders, trigger removal), still show slow blood glucose decline (less than 30% of baseline within 4 hours), difficult-to-correct ketone bodies, or repeated fluctuations. These are defined as refractory DKA, often associated with sustained excessive secretion of glucagon and other counter-regulatory hormones, severe insulin resistance, infection, or multiple organ dysfunction. Delayed treatment adjustment may worsen the condition and increase risks of coma, organ damage, and death. According to the American Diabetes Association (ADA), refractory DKA accounts for about 8%–12% of all DKA cases, with a mortality rate 3–4 times higher than ordinary DKA. Effective adjuvant therapy is therefore critical.

When combined with conventional treatment for refractory DKA, the product can strongly inhibit glucagon secretion, rapidly block gluconeogenesis and ketogenesis, and synergize with insulin to lower blood glucose and correct ketosis, significantly improving therapeutic effects. Clinical studies from the ADA show that two children with refractory DKA continued to have blood glucose above 1300 mg/dl, no improvement in consciousness, and rising blood ketones despite standard insulin and fluid therapy. After adding somatostatin analogs (oral forms can serve as a transition from intravenous formulations), their blood glucose gradually decreased to below 800 mg/dl within 4 hours, ketosis was effectively relieved, consciousness recovered within 3–4 hours, and blood glucose and ketones normalized within 72 hours, indicating significant adjuvant efficacy in refractory DKA.

Accidental Discovery: Early Clues to Somatostatin (1956–1969)

The discovery of Somatostatin (SST) was an accidental scientific breakthrough. It was initially identified as an inhibitory substance unexpectedly observed while researchers were searching for Growth Hormone-Releasing Factor (GRF). In 1956, Polish postgraduate Krulich first focused on the regulation of growth hormone. Subsequent experiments revealed that hypothalamic extracts could inhibit growth hormone secretion from the pituitary gland, which was completely contrary to the expected stimulatory effect. In 1968, Krulich's team officially reported the presence of Growth Hormone Release-Inhibiting Factor (GRIF/GIF) in the hypothalamus. In 1969, Hellman and Lernmark discovered a substance capable of inhibiting insulin secretion in pancreatic islet extracts. These two major findings laid the foundation for subsequent systematic research.

Structural Elucidation: From Crude Extract to Purified Compound (1972–1973)

In 1972, the team led by Roger Guillemin at the Salk Institute for Biological Studies in the United States, with Paul Brazeau as a core member, restarted research to confirm the authenticity of this inhibitory factor. The team performed purification from ovine hypothalamic extracts and isolated 8 mg of the active substance within several months. In 1973, its structure was successfully elucidated as a cyclic peptide consisting of 14 amino acids (SST-14), and the substance was chemically synthesized artificially. Guillemin named it "Somatostatin", meaning a substance that inhibits growth hormone. The relevant findings were published in Science, marking a milestone in the field of neuroendocrinology.

Subsequent Development: From a Single Factor to a Pleiotropic Hormone (1974–Present)

After 1974, studies demonstrated that somatostatin is not confined to the hypothalamus; it is widely distributed in the central nervous system, gastrointestinal tract, pancreas and other tissues, with multiple isoforms such as SST-28 composed of 28 amino acids identified. In 1977, Guillemin was awarded the Nobel Prize in Physiology or Medicine for his research on hypothalamic hormones. The discovery and clinical applications of somatostatin, including the treatment of gastrointestinal hemorrhage and neuroendocrine tumors, have continuously advanced the development of endocrinology and pharmacology.